Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2022 · 10-Q
Revenue$682.00K$682.00K±0.0% vs Q3 2021 Net Income-$7.06M-$7.06MN/M vs Q3 2021 EPS Diluted$0.18$0.18−14.3% vs Q3 2021 Operating Income-$8,189,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,362,000N/M Margins · derivedOperating margin-1200.7%−103.2 pt vs Q3 2021
Net margin-1035.2%+69.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end